Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Med
Autors principals: Saei, Azad, Palafox, Marta, Benoukraf, Touati, Kumari, Nishi, Jaynes, Patrick William, Iyengar, Prasanna Vasudevan, Muñoz-Couselo, Eva, Nuciforo, Paolo, Cortés, Javier, Nötzel, Christopher, Kumarakulasinghe, Nesaretnam Barr, Richard, John Lalith Charles, Bin Adam Isa, Zul Fazreen, Pang, Brendan, Guzman, Marta, Siqin, Zhou, Yang, Henry, Tam, Wai Leong, Serra, Violeta, Eichhorn, Pieter Johan Adam
Format: Artigo
Idioma:Inglês
Publicat: Rockefeller University Press 2018
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6028519/
https://ncbi.nlm.nih.gov/pubmed/29880484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20171960
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars